Syndax Announces Participation In BTIG Virtual Biotechnology Conference

WALTHAM, Mass., Aug.
Author:
Publish date:

WALTHAM, Mass., Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:00 p.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.       

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit  www.syndax.com or follow the Company on  Twitter and  LinkedIn

Syndax Contacts

Investor Contact Melissa ForstArgot Partners melissa@argotpartners.comTel 212.600.1902

Media Contact Ted Held ted.held@gcihealth.com Tel 212.798.9842

SNDX-G

View original content: http://www.prnewswire.com/news-releases/syndax-announces-participation-in-btig-virtual-biotechnology-conference-301104238.html

SOURCE Syndax Pharmaceuticals, Inc.